Clevudine

Source: Wikipedia, the free encyclopedia.
Clevudine
Clinical data
Routes of
administration		Oral
ATC code
Identifiers
  • 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione
JSmol)
  • O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)[C@H]2F)CO
  • InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1 ☒N
  • Key:GBBJCSTXCAQSSJ-XQXXSGGOSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Clevudine (

INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines
. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Researchers in South Korea are testing clevudine at lower doses in combination with adefovir for continued use.[2]

It is a

nucleoside analog.[3]

References

  1. ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
  2. PMID 25101150
    .
  3. PMID 16628625
    .


drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Clevudine&oldid=1172005697"